Clarity advances to cohort 2 in the SARTATE™ neuroblastoma trial
- Written by PR Newswire Asia - Daily Bulletin Au RSS
- Cohort 1 completed in 3 participants with neuroblastoma who received therapy with 67Cu SARTATE™ at a dose of 75MBq/kg body weight
- No dose limiting toxicities (DLTs) have been reported in cohort 1
- The Safety Review Committee (SRC) has recommended the trial continues with the dose escalation phase as planned
- Recruitment is open at all...
Read more: Clarity advances to cohort 2 in the SARTATE™ neuroblastoma trial